The compound was first characterized in 2015, where it was reported to act on the folate–methionine cycle and downstream one-carbon metabolism, with accumulation of the purine intermediate AICAR and subsequent AMPK activation observed in cell and rodent models [1]. That AMPK-linked mechanism has anchored most subsequent laboratory work.

A 2018 study reported that MOTS-c translocates from the cytosol to the nucleus under metabolic stress and interacts with stress-responsive transcription factors including NFE2L2/NRF2 at antioxidant response elements [2]. This is the basis for describing the molecule as a mitochondrial-to-nuclear signal rather than a purely cytosolic one. Work on glucose transporter handling has been examined alongside it, with one study reporting that OPA1 and MFN2 mediated mitochondrial fusion was required for MOTS-c associated GLUT4 translocation in cultured mammalian cell and adipocyte models [3]. Researchers comparing mitochondrial-targeted compounds may find the SS-31 and MOTS-c comparison guide useful context, as is the overview of how NAD+ differs structurally from peptides.

The research threads below cover the two areas where published data is most developed.

Kinase Binding and Skeletal Muscle Signaling

A 2024 cell-free binding study reported that MOTS-c binds directly to protein kinase CK2 and activates it, with tissue-differential activity observed between skeletal muscle and adipose tissue [4]. An earlier report described a CK2 to PTEN to mTORC2 to AKT to FOXO1 cascade associated with reduced myostatin expression in C2C12 myotubes exposed to palmitic acid [5].

Myogenic Differentiation Models

In vitro work in LHCN-M2 and C2C12 myoblast lines reported increased myotube formation following exposure to wild-type MOTS-c, an outcome not observed with the Y8F mutant variant, which points to a defined sequence region as the active site [6].

Exercise-responsive expression has also been examined in study populations and rodent models, where circulating levels were reported to change with physical activity and with age [7]. Broader reviews place MOTS-c within the wider mitochondrial-derived peptide family studied in aging research models [8].

Certificate of Analysis (COA) for Every Batch

A Certificate of Analysis (COA) is a document that verifies a compound’s identity, purity, and batch quality through independent laboratory testing. Every compound from BioLongevity Labs ships with a COA tied to its specific batch, so researchers can confirm exactly what they received before it enters a protocol.

Each COA reports results from third-party laboratory analysis, including:

• High-performance liquid chromatography (HPLC) for purity, typically confirmed at 99% or higher
• Liquid chromatography mass spectrometry (LC-MS) for molecular identity and mass confirmation
• Sterility and endotoxin screening where applicable
• Chemical contaminant and residual solvent checks

COAs are sourced from independent certified labs rather than in-house testing alone, giving researchers a verifiable record of molecular integrity for each batch. All compounds are supplied for research use only.